Michael Curtis, PhD

Dr. Curtis is the President and Chief Executive Officer at eGenesis and is responsible for managing the development of eGenesis’ xenotransplantation programs. Dr. Curtis is a seasoned biotech executive recognized for advancing therapeutic innovation across transplant, neuroscience, oncology, and rare disease. He brings a unique blend of scientific depth and operational expertise, having contributed to numerous INDs, several approved therapies, and first-in-class clinical programs. As a founder and builder, Dr. Curtis has helped launch five biotech companies and raised over $625M in capital, driving significant value creation. He excels at bridging translational science with company-building, scaling teams and platforms from concept to clinic. As CEO of eGenesis, he now leads efforts to develop gene-edited porcine organs for human transplantation to address the global organ shortage. His leadership reflects a rare combination of strategic vision, technical depth, and mission-driven execution.